Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05579405Unknown

sCLEC-2 in Stroke Study

Role: lead

NCT01149902Phase 1Unknown

Study of Chemo-Immunotherapy in Head and Neck Cancer Patients

Role: lead

NCT01267578Phase 2Unknown

Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)

Role: lead

NCT00995358Phase 2Unknown

A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer

Role: lead

NCT00682227Phase 1Unknown

Peptide Vaccination in Treating Patients With Esophageal Cancer

Role: lead

All 5 trials loaded